Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

14.4 -1.44

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.33

Max

14.71

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+101.37% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	57M 1.2B
Vorheriger Eröffnungskurs	15.84
Vorheriger Schlusskurs	14.4

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Sept. 2026, 23:56 UTC

C.H. Robinson Worldwide shares are lower in after-market trading, despite a broader market rally amid reduced interest rate hike expectations.

3. Sept. 2026, 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

3. Sept. 2026, 23:56 UTC

SiTime Corp shares are lower in after-market hours, continuing a decline that began earlier, despite gains in major indices.

3. Sept. 2026, 23:56 UTC

Elme Communities shares traded roughly flat in after-market hours. Broader market trends reflect gains in major averages amid reduced interest rate hike expectations.

3. Sept. 2026, 23:56 UTC

News

Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

3. Sept. 2026, 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

3. Sept. 2026, 23:56 UTC

Tapestry Inc. shares rose slightly in after-market trading, reflecting broader market gains amid reduced interest rate hike expectations. They remain below their 20-day moving average.

3. Sept. 2026, 23:56 UTC

Loews Corp shares are higher in after-market hours, reflecting broader market gains amid reduced interest rate hike expectations.

3. Sept. 2026, 23:56 UTC

Union Pacific Corp shares are higher in after-market trading, following gains in major indices amid reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3. Sept. 2026, 23:56 UTC

Sportsman's Warehouse shares advanced in after-market trading, reflecting broader market gains amid reduced expectations for an interest rate hike.

3. Sept. 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

3. Sept. 2026, 23:56 UTC

General Motors traded roughly flat after-market hours amid strong market momentum driven by reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3. Sept. 2026, 23:56 UTC

Wingstop Inc shares are trading higher in after-market hours, supported by strong gains in major indices amid reduced interest rate hike expectations, according to CME Group.

3. Sept. 2026, 23:51 UTC

Exelon Corp shares are lower in after-market hours, diverging from broader market gains amid anticipation of upcoming employment data. No specific news was identified.

3. Sept. 2026, 23:51 UTC

Japan's Household Spending Falls 3.6% YoY in July, Marking Eighth Straight Month of Decline Amid Economic Uncertainty

3. Sept. 2026, 23:51 UTC

Japan's Household Spending MoM for July rises 0.5%, falling short of 2.6% expectations, raising concerns over consumer behavior amid a year-on-year decline of 3.6%.

3. Sept. 2026, 23:51 UTC

Canada's Ivey PMI forecasted to rise to 56.2 in August, signaling cautious optimism amid mixed business confidence trends and regional recovery signals.

3. Sept. 2026, 23:51 UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

3. Sept. 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

3. Sept. 2026, 23:51 UTC

News

Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

3. Sept. 2026, 23:51 UTC

Yelp Inc shares are higher in after-market trading, following gains in the broader market. No specific company news was identified to explain the movement.

3. Sept. 2026, 23:51 UTC

News

Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

3. Sept. 2026, 23:51 UTC

Shake Shack Inc shares are lower in after-market hours, continuing a downward trend below the 20-day moving average and nearing the one-month range low.

3. Sept. 2026, 23:46 UTC

Hilton Worldwide Holdings Inc shares are trading higher in after-market hours, supported by gains in major indices amid anticipation of Friday's employment report.

3. Sept. 2026, 23:46 UTC

Correlated Moves

Kimco Realty Corp shares are lower in after-market hours, reflecting a decline since Thursday's close. Broader market trends also show weakness.

3. Sept. 2026, 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

3. Sept. 2026, 23:46 UTC

FedEx Corp shares are lower in after-market trading, reflecting a decline from Thursday's close. The stock showed initial strength before pulling back.

3. Sept. 2026, 23:46 UTC

Correlated Moves

AMETEK Inc. shares declined in after-market trading, reflecting broader small-cap market trends amid significant gains in major indices earlier in the session.

3. Sept. 2026, 23:46 UTC

Correlated Moves

Box Inc shares are lower in after-market hours following significant volatility. The decline may be linked to a drop in Asana Inc's stock.

3. Sept. 2026, 23:46 UTC

Marcus & Millichap shares are lower in after-market trading, despite broader market gains. No specific news was identified to explain the decline.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

101.37% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 101.37%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.